Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Analyst: Biotech to Have 'Eventful Year' with Data Readouts in Three Indications

This California company expects results from clinical trials in liver disease and psoriasis in 2019. In a March 8 research note, H.C. Wainwright & Co. analyst Ed Arce reported that DURECT Corp. (DRRX:NASDAQ) continues advancing clinical trials evaluating its lead prod...
Streetwise Reports | March 14, 2019 |

Gold’s Seasonal Outlook for Q4

“What is the best predictor of future behavior? Past behavior.” And while this certainly does not always hold, there is a lesson to be learned from this adage for gold investors. Yup, a saying about behavior might be important for the precious metals mark...
Mike McAra | October 23, 2019 |

Increased Cannabis Interest Paves Way for Cannabinoid Production

As the cannabis market has started to recover amidst the COVID-19 pandemic, investors are looking at where the market can grow. One leading candidate is cannabinoid production. THC, CBD, and other specific cannabinoids can be useful for a variety of treatments, includ...
Omri Wallach | June 9, 2020 |

Gold in the Saskatchewan Trans Hudson Corridor

SKRR Exploration ( TSX-V: SKRR , Forum ) is drilling at the Olson Gold Project and then will move the drills to a similar size program at the historic Manson Bay occurrence in proximity to the Flin Flon ore body. SKRR is actively drilling in the massive Trans Hudson...
Featured Submission | February 23, 2022 |

Silver’s Q4 Seasonal Outlook

What has been will be again, what has been done will be done again; there is nothing new under the sun. Ecclesiastes 1:9 History repeats itself. Not always, and not 100%, but often enough and to an extent that’s significant enough to make these repet...
Mike McAra | October 2, 2019 |

Adaptimmune Shares Triple as SPEAR T-cell Platform Delivers Initial Responses ...

Adaptimmune Shares Triple as SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications Shares of Adaptimmune Therapeutics more than tripled in value after the company reported that its SPEAR T-cell platform delivered positive initial responses in...
Streetwise Reports | January 14, 2020 |

Coverage Initiated on U.S. Biotech with a 'Potential Best-of-Breed Oncolytic Virus'

The investment thesis on this immunotherapies developer is made in an H.C. Wainwright & Co. report. Analyst Ram Selvaraju reported in a July 8 research note that H.C. Wainwright & Co. initiated coverage on Replimune Group Inc. (REPL:NASDAQ) with a Buy ...
Streetwise Reports | July 11, 2019 |

Several Data Catalysts Expected in 2019 for 'Underappreciated Story'

An H.C. Wainwright & Co. report discussed what those are and why they could impact the biotech's valuation. In a March 18 research note, H.C. Wainwright & Co. analyst Andrew Fein purported that Constellation Pharmaceuticals Inc.'s (CNST:NASDAQ) "strong and balanced pi...
Streetwise Reports | March 25, 2019 |

Precision Medicine Firm Announces 'Positive' Data in Lymphoma Study

The highlights of the results were presented in an H.C. Wainwright & Co. report. In a June 14 research note, H.C. Wainwright & Co. analyst Joseph Pantginis reported that Kura Oncology Inc. (KURA:NASDAQ) met the endpoint in its Phase 2 clinical trial of...
Streetwise Reports | June 21, 2019 |

Truly Epic Silver Signals: Vying for Your Attention

If we had to pick one day, or one situation when a single market provided most indications during a single day, it would be yesterday’s performance of silver. There’s not much to say about yesterday’s session while looking at...
Przemyslaw Radomski, CFA | July 17, 2019 |
1 2 3 4 5 6 7 8 9 10 ...